Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Source: Reuters
- Implied Volatility (expected price movement) for short-dated options is 27%
- Realized Volatility (historic price movement) for short-dated options is 25%
- Implied Volatility Percentile for short-dated options is 44%
Yesterday’s close price triggered a long momentum signal based on one of our proprietary strategies. If you are bullishly disposed, you may want to consider the following trade structure:
Trade Structure Profit Target.
Close the Trade Structure after if the fair market value is <50% of Net Debit Paid.